SGLT2 Inhibitors and Bone Health: What You Need to Know About Fracture Risk

When you're managing type 2 diabetes, choosing the right medication isn't just about lowering blood sugar. It's about protecting your whole body - heart, kidneys, and yes, even your bones. SGLT2 inhibitors have become popular for their ability to reduce heart failure and kidney damage in people with diabetes. But for years, one question kept coming up: Do these drugs increase your risk of breaking a bone? The answer isn't simple. It depends on which drug you're taking - and who you are.

Not All SGLT2 Inhibitors Are the Same

There are three main SGLT2 inhibitors used today: canagliflozin (Invokana), empagliflozin (Jardiance), and dapagliflozin (Farxiga). All of them work the same way - they stop the kidneys from reabsorbing sugar, so excess glucose leaves the body through urine. But when it comes to bone health, they don't act the same.

Canagliflozin is the only one with a clear, FDA-mandated warning about fractures. In the CANVAS trial, people taking 300 mg of canagliflozin had 26% more fractures than those on placebo. Most of these were in the arm, hand, foot, or upper leg, and they happened after minor falls - like tripping over a rug or slipping in the shower. The risk showed up as early as 12 weeks after starting the drug.

Now look at empagliflozin and dapagliflozin. In the EMPA-REG OUTCOME and DECLARE-TIMI 58 trials - which together tracked over 18,000 patients - there was no increase in fracture risk. A 2023 meta-analysis of 27 studies involving nearly 21,000 people found the overall risk with SGLT2 inhibitors was essentially unchanged: a relative risk of 1.02. That’s not statistically different from zero. So if you're on empagliflozin or dapagliflozin, your fracture risk is likely no higher than if you were on any other diabetes drug.

Why Does Canagliflozin Pose a Risk?

Scientists aren't sure exactly why canagliflozin stands out. But several clues point to a combination of factors:

• Bone density loss: In a 2-year FDA-required study, people taking canagliflozin lost 0.92% of hip bone density and 1.04% from the spine. Placebo users lost only 0.24% and 0.44%. That’s not massive, but it’s real - and enough to matter in older adults.
• Weight loss: SGLT2 inhibitors typically cause a 2-4 kg weight drop. While that’s good for blood sugar, losing weight can reduce mechanical stress on bones, which may lead to lower bone formation. But studies show weight loss explains less than 3% of the bone density changes seen.
• Calcium and phosphate shifts: These drugs increase phosphate reabsorption in the kidneys. That triggers hormones like PTH and FGF23, which can pull calcium out of bone. It’s a subtle effect, but over time, it adds up.
• Hormonal changes: Women on canagliflozin 300 mg saw a 9.2% drop in estradiol - a hormone that helps keep bones strong. This didn’t happen with other SGLT2 inhibitors.
• Low blood pressure: About 1 in 100 people on canagliflozin get dizzy or lightheaded when standing up. That increases fall risk - and falls are what cause most fractures.

These factors don’t all show up with empagliflozin or dapagliflozin. That’s why the FDA only flagged canagliflozin - not the whole class.

Who Should Avoid Canagliflozin?

You don’t need to stop all SGLT2 inhibitors. But if you’re at high risk for fractures, you should be careful with canagliflozin.

The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology say: avoid canagliflozin if you have:

• A prior fracture (especially after age 50)
• Osteoporosis (T-score ≤ -2.5 on a DXA scan)
• Multiple risk factors: age over 70, long-term steroid use, low body weight, or history of falls

For these people, the risks outweigh the benefits. The American Geriatrics Society even lists canagliflozin as a "potentially inappropriate medication" for older adults with osteoporosis - a rare designation.

Empagliflozin and dapagliflozin? No such restrictions. If you're older, have weak bones, or are prone to falls, these are safer choices. In fact, some studies suggest they might carry equal or even lower fracture risk than GLP-1 agonists or DPP-4 inhibitors.

What Should You Do?

If you’re already on an SGLT2 inhibitor:

• If you’re on canagliflozin and have no history of fractures or low bone density, you’re likely fine - but talk to your doctor about monitoring.
• If you’re on canagliflozin and have had a fracture, osteoporosis, or are over 70 - ask if switching to empagliflozin or dapagliflozin makes sense.
• If you’re on empagliflozin or dapagliflozin, don’t panic. There’s no strong evidence linking them to fractures.

If you’re considering starting one:

• Ask for a bone density scan (DXA) if you’re over 65, have had a fracture, or have other risk factors.
• Use the FRAX tool - it’s a free online calculator that estimates your 10-year fracture risk. The ADA now adds 0.5 points to your score if you’re prescribed canagliflozin. That’s a small bump, but it matters in borderline cases.
• Ask your doctor: "Which SGLT2 inhibitor are you recommending - and why?" Don’t assume they’re all the same.

Real-World Experience

A 2022 survey of 347 endocrinologists found that 68% adjust their prescriptions based on fracture risk. Of those, 82% avoid canagliflozin in patients with osteoporosis. Only 34% were cautious with dapagliflozin. That’s a big gap.

On patient forums, 78% of people with diabetes expressed concern about fractures on SGLT2 inhibitors. But when you look at the data, most of those fears are tied to canagliflozin. In one clinic, 23 patients reported falls on canagliflozin versus just 7 on empagliflozin. That’s not random - it’s pattern.

Still, some doctors report no difference. Johns Hopkins tracked over 15,000 patients and found no statistically significant rise in fractures between SGLT2 types after adjusting for age and fall risk. So why the disconnect? It might be that most studies are too short. The average trial lasts 2-3 years. But fractures in older adults often happen after 5 or 10 years. We still need longer data.

What’s Changing Now?

The 2023 American Diabetes Association guidelines finally made it clear: "SGLT2 inhibitors as a class do not appear to increase fracture risk, though canagliflozin specifically has shown modest increases in some studies."

The FDA hasn’t changed its label for empagliflozin or dapagliflozin since 2018. The European Medicines Agency still warns about bone effects across the whole class - but even they don’t single out any drug beyond canagliflozin.

Prescription trends tell the story. Between 2017 and 2022, canagliflozin use dropped 22% in the U.S. Empagliflozin and dapagliflozin rose by 38% and 42%. That’s not because they’re cheaper. It’s because doctors are choosing safer options.

And the next big update - the 2024 ADA/EASD consensus report - is expected to give even clearer guidance: algorithms for who should get a bone scan before starting any SGLT2 inhibitor.

Bottom Line

SGLT2 inhibitors are powerful tools. They save hearts and kidneys. But they’re not all equal when it comes to bones.

Canagliflozin carries a small but real fracture risk - especially in older adults, those with low bone density, or anyone who’s fallen before. If you’re in that group, don’t take it. Switch to empagliflozin or dapagliflozin. They work just as well for blood sugar, heart health, and kidneys - without the bone risk.

For everyone else? You’re probably fine. But always ask: "Is this the right drug for my whole body?" Not just your blood sugar - your bones matter too.